Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 4.250

-0.7%

Sep 6 3:52 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Ox who wrote (3312)	10/19/2011 5:37:10 PM
From: FJB	1 Recommendation Read Replies (1) of 3566

Geron’s Embryonic Stem Cell Clinical Trial for Spinal Cord Injury – Video 57:29 run time youtu.be Dr. Jane Lebkowski, executive vice president and chief scientific officer at Geron Corporation, gave the keynote address for the 2011 CIRM Bridges Trainee Meeting. Last year, Geron began the first clinical trial in the world using human embryonic stem cells. CIRM recently approved a $25 million loan to Geron to assist in this trial. The embryonic stem cells used in the trial are being tested as a potential therapy for spinal cord injury. Lebkowski reviewed the work leading up to the trial and gave the latest update on its progress. Lebkowski was introduced by Art Torres, vice chair of the CIRM Governing Board, and Pat Olson, executive director of CIRM scientific activities.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next